Biogen Inc.

BIIB Healthcare Drug Manufacturers General

Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.

232.65 2.70 −1.15%
Market cap
$34.8B
P/E
41.0×
Fwd P/E
31.5×
Dividend yield
—
F-score
4/9
Altman Z
3.13
Beneish M
−2.67
Dividend safety
n/a

Biogen Inc. (BIIB) EV/FCF

Alert me on EV/FCF

As of 16 October 2026, Biogen Inc. (BIIB) trades at a EV/FCF of 15.9×. Over the past ten years it has ranged from −1,928× (April 2015) to 42.2× (October 2023); the current reading is higher than 57% of that period.

EV/FCF, daily

Embed this chart

Annual newest first

Period EV/FCF Change
FY2025 14.0× 44.05%
FY2024 9.7× (73.01%)
FY2023 36.0× 51.30%
FY2022 23.8× 109.17%
FY2021 11.4× (5.40%)
FY2020 12.0× 38.82%
FY2019 8.7× (28.33%)
FY2018 12.1× (57.33%)
FY2017 28.3× 67.30%
FY2016 16.9× (25.82%)

Quarterly newest first

Period EV/FCF Change
Jun 2026 14.9× 23.64%
Mar 2026 12.1× (13.71%)
Dec 2025 14.0× 38.46%
Sep 2025 10.1× (14.88%)
42 more quarters

Against its own ten years

Low −1,928× High 42.2×
Ten-year median 14.5×
Current reading's percentile 56

EV/FCF against peers

What EV/FCF is

EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))

The full definition of EV/FCF →

More on BIIB